TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31890996

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (LLT) including statin and/or ezetimibe
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (LLT)
Number of subjects: 3033
Study: 31891134

Group type: EXPERIMENTAL
Intervention: Standard condoms
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Thin condoms
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Condoms fitted to each user's penile dimensions
Number of subjects: 504
Study: 31891135

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX followed by Stereotactic Body Radiotherapy (SBRT) (5 fractions/8 Gy)
Number of subjects: 50
Study: 31891145

Group type: EXPERIMENTAL
Intervention: GAIN+EUC
Number of subjects: 112

Group type: COMPARATOR
Intervention: EUC
Number of subjects: 112
Study: 31891235

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 216

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: INCREMENT-CPE mortality score ≥8
Number of subjects: 216
Study: 31891447

Group type: EXPERIMENTAL
Intervention: Hypertensive patients with diabetes
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Hypertensive patients without diabetes
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1443
Study: 31891695

Group type: EXPERIMENTAL
Intervention: PCEA (patient-controlled epidural analgesia)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Posterolateral thoracotomy
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Anterolateral thoracotomy
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 344
Study: 31891878

Group type: EXPERIMENTAL
Intervention: Letrozole combined with CDK inhibition
Number of subjects: 30
Study: 31891967

Group type: EXPERIMENTAL
Intervention: Embrace WetBond sealant
Number of subjects: 90

Group type: COMPARATOR
Intervention: ART sealant
Number of subjects: 90
Study: 31892445

Group type: EXPERIMENTAL
Intervention: One-piece patient-specific reconstruction plate for double-barrel fibula flap reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard reconstruction methods (implied control)
Number of subjects: 0
Study: 31892518

Group type: EXPERIMENTAL
Intervention: TST
Number of subjects: 3593

Group type: EXPERIMENTAL
Intervention: QFT-GIT
Number of subjects: 3593

Group type: EXPERIMENTAL
Intervention: T-SPOT
Number of subjects: 3593

Group type: COMPARATOR
Intervention: TST-positive, IGRA-negative results
Number of subjects: 3593
Study: 31892644

Group type: EXPERIMENTAL
Intervention: Standardised approach to patient education about cardiovascular risk factors, physical activity (PA), and a healthy diet integrated into existing rehabilitation settings.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control from a prospective national cohort study on body mass index (BMI).
Number of subjects: 0
Study: 31892671

Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery (TORS) with tailored radiotherapy
Number of subjects: 25
Study: 31893018

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Number of subjects: 0
Study: 31893211

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Presence of inclusion bodies
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-grade positivity on IHC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Colonic CMV viral load
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Blood CMV viral load
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mayo score and blood CMV expression
Number of subjects: 80
Study: 31893514

Group type: EXPERIMENTAL
Intervention: AAV5-hFVIII-SQ gene therapy
Number of subjects: 15
Study: 31894377

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment in treatment-naïve patients
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment in previously treated patients
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 147
Study: 31894702

Group type: EXPERIMENTAL
Intervention: Motivational survey and tailored advertising campaign
Number of subjects: 7059

Group type: EXPERIMENTAL
Intervention: Unpaid media events
Number of subjects: 7059

Group type: EXPERIMENTAL
Intervention: Print media characteristics
Number of subjects: 7059

Group type: EXPERIMENTAL
Intervention: Media events
Number of subjects: 7059
Study: 31894704

Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine in combination with immune-checkpoint inhibitors
Number of subjects: 71
Study: 31895148

Group type: EXPERIMENTAL
Intervention: Machine learning analysis using gradient-boosted multivariate regressions (GBM)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Longitudinal predictors with GBM
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Mental health problems and hematocrit levels in longitudinal models
Number of subjects: 285

Group type: COMPARATOR
Intervention: Machine learning vs logistic regression
Number of subjects: 285
Study: 31895484

Group type: EXPERIMENTAL
Intervention: Web-based training on NICE classification
Number of subjects: 30

Group type: COMPARATOR
Intervention: No training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-confidence level
Number of subjects: 30
Study: 31895611

Group type: EXPERIMENTAL
Intervention: AMG 420 at 400 μg/d (maximum tolerated dose)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AMG 420 at 0.2-800 μg/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AMG 420 at 800 μg/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AMG 420 at 400 μg/d
Number of subjects: 42
Study: 31895695

Group type: EXPERIMENTAL
Intervention: Morning exercise (10 hours after DLMO)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Evening exercise (20 hours after DLMO)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Morning exercise for later chronotypes
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Evening exercise for later chronotypes
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Morning exercise for earlier chronotypes
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Evening exercise for earlier chronotypes
Number of subjects: 52
Study: 31895696

Group type: EXPERIMENTAL
Intervention: U-mtDNA levels in smokers without COPD
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: U-mtDNA levels in males
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: U-mtDNA levels in females
Number of subjects: 483

Group type: COMPARATOR
Intervention: UACR levels
Number of subjects: 483
Study: 31895987

Group type: EXPERIMENTAL
Intervention: Computed Tomography Airway Count
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31896448

Group type: EXPERIMENTAL
Intervention: Higher plasma concentration of UCHL1
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: BDNF plasma concentration
Number of subjects: 427
Study: 31896519

Group type: EXPERIMENTAL
Intervention: Lurbinectedin/doxorubicin (Stratum A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lurbinectedin/gemcitabine (Stratum B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lurbinectedin monotherapy (Stratum C)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lurbinectedin (all strata)
Number of subjects: 42
Study: 31896540

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Score
Number of subjects: 632
Study: 31897475

Group type: EXPERIMENTAL
Intervention: Viscous fiber
Number of subjects: 3877
Study: 31897676

Group type: EXPERIMENTAL
Intervention: Etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) combination chemotherapy
Number of subjects: 0
Study: 31897939

Group type: EXPERIMENTAL
Intervention: Visual Scanning Test (VST)
Number of subjects: 86
Study: 31898051

Group type: EXPERIMENTAL
Intervention: EndoZip™ system for gastric volume reduction
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EndoZip™ system
Number of subjects: 11
Study: 31898110

Group type: EXPERIMENTAL
Intervention: Endoscopic papillectomy (EP)
Number of subjects: 62
Study: 31898493

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) at a low dose of 75μg/d for 1 month, adjusted to 150μg/d if lesions did not improve, for a total treatment duration of 6 months.
Number of subjects: 24
Study: 31898757

Group type: EXPERIMENTAL
Intervention: Optimal blood pressure control
Number of subjects: 200
Study: 31899729

Group type: EXPERIMENTAL
Intervention: Cholic acid (10-15 mg·kg·day)
Number of subjects: 53
Study: 31899873

Group type: EXPERIMENTAL
Intervention: BBBD with MR-guided focused ultrasound (MRgFUS) during adjuvant TMZ chemotherapy
Number of subjects: 6
Study: 31900121

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg i.v. every 2 weeks for 4 cycles preoperatively with concomitant radiation therapy of bladder and pelvic region (max. 50.4 Gy)
Number of subjects: 33
Study: 31900186

Group type: EXPERIMENTAL
Intervention: Acellular porcine corneal stroma (APCS) transplantation
Number of subjects: 39
Study: 31900292

Group type: EXPERIMENTAL
Intervention: HFD gut microbes transplantation (HFD-FMT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: ND gut microbes transplantation
Number of subjects: 2
Study: 31900808

Group type: EXPERIMENTAL
Intervention: ER or PR+/Her2neu-
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Her2neu+
Number of subjects: 734

Group type: COMPARATOR
Intervention: ER and PR-/Her2neu-
Number of subjects: 734
Study: 31901436

Group type: EXPERIMENTAL
Intervention: Increased ReHo in the bilateral dorsal anterior cingulate cortex (dACC)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Increased ReHo in the right middle temporal gyrus
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Lower functional connectivity between the dACC and the precuneus
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cognitive performance and executive functions measured with Dementia Rating Scale, Trail-Making Test (A and B), Stroop Color Word Test, and Digit Span Test
Number of subjects: 76
Study: 31901758

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 6508
Study: 31902278

Group type: EXPERIMENTAL
Intervention: Patients with SDB (57 patients)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Patients without SDB (56 patients)
Number of subjects: 113
Study: 31902325

Group type: EXPERIMENTAL
Intervention: Preexisting cognitive impairment identified using the 16-item Informant Questionnaire for Cognitive Decline in the Elderly
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Presence of lacunes
Number of subjects: 1102
Study: 31902458

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) for STSE, 30% (8/27) of responders routinely treated STSE with IMRT.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 27
Study: 31902581

Group type: EXPERIMENTAL
Intervention: Risperidone (16-week trial)
Number of subjects: 55
Study: 31902592

Group type: EXPERIMENTAL
Intervention: Skip metastases (pN0N2)
Number of subjects: 2653

Group type: COMPARATOR
Intervention: N2 non-small cell lung cancer without skip metastases
Number of subjects: 2653
Study: 31902946

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 167
Study: 31903182

Group type: EXPERIMENTAL
Intervention: R-CHOP plus B-cell receptor/NF-κB-double-targeting
Number of subjects: 0
Study: 31904267

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 0
Study: 31905039

Group type: EXPERIMENTAL
Intervention: Person-Centered Narrative Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 31905352

Group type: EXPERIMENTAL
Intervention: Growth rate measurements in patients with geographic atrophy (GA)
Number of subjects: 112
Study: 31905377

Group type: EXPERIMENTAL
Intervention: hs-cTnI cutoff of 2.5 ng/L
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: hs-cTnT concentrations less than 5 ng/L
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: hs-cTnI concentrations less than 2 ng/L
Number of subjects: 1896
Study: 31905403

Group type: EXPERIMENTAL
Intervention: Postpartum weight loss group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Postpartum weight retention group
Number of subjects: 37
Study: 31906435

Group type: EXPERIMENTAL
Intervention: Open-Label Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deceptive Placebo
Number of subjects: 0
Study: 31906738

Group type: EXPERIMENTAL
Intervention: Quantitative faecal immunochemical test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptoms suspected for colorectal cancer
Number of subjects: 0
Study: 31906829

Group type: EXPERIMENTAL
Intervention: Precision grip force control intervention (Strength-Dexterity test)
Number of subjects: 80
Study: 31906923

Group type: EXPERIMENTAL
Intervention: Observational cohort study with community health workers (Especialistas) conducting research activities and data collection.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Cohort study framework for diabetes research and care.
Number of subjects: 1000
Study: 31907067

Group type: EXPERIMENTAL
Intervention: EPAD longitudinal cohort study (EPAD-LCS) participation
Number of subjects: 16877

Group type: EXPERIMENTAL
Intervention: Clinical cohort prescreening
Number of subjects: 16877

Group type: EXPERIMENTAL
Intervention: Research in-person cohort prescreening
Number of subjects: 16877

Group type: EXPERIMENTAL
Intervention: Research online cohort prescreening
Number of subjects: 16877

Group type: EXPERIMENTAL
Intervention: Population-based cohort prescreening
Number of subjects: 16877

Group type: EXPERIMENTAL
Intervention: Amyloid positivity among EPAD-LCS participants
Number of subjects: 16877

Group type: EXPERIMENTAL
Intervention: Factors predicting participation in EPAD-LCS
Number of subjects: 16877

Group type: EXPERIMENTAL
Intervention: Factors predicting amyloid positivity among EPAD-LCS participants
Number of subjects: 16877
Study: 31907183

Group type: EXPERIMENTAL
Intervention: High-Dose Chloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-Dose Chloroquine
Number of subjects: 0
Study: 31907538

Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Higher HbA1c
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lower adrenocorticotropin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: BMD correlation with parathyroid hormone, FGF23, thyrotropin, and glycated hemoglobin (HbA1c) levels
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fracture history
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mean final heights
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Abnormal BMD
Number of subjects: 29
Study: 31907737

Group type: EXPERIMENTAL
Intervention: Whole genome and transcriptome analysis (WGTA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Matched treatment based on molecular targets
Number of subjects: 28

Group type: COMPARATOR
Intervention: Single-gene DNA changes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Genome-wide data or RNA gene expression
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Treatment duration
Number of subjects: 28
Study: 31907828

Group type: EXPERIMENTAL
Intervention: acarbose 50 mg for 1 week
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg for 1 week
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: verapamil 120 mg for 1 week
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg for 3 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: pasireotide 300 μg as a single dose
Number of subjects: 11

Group type: COMPARATOR
Intervention: baseline liquid mixed meal test (MMT)
Number of subjects: 11
Study: 31908107

Group type: EXPERIMENTAL
Intervention: Abstinent alcohol-dependent patients
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Subjective craving
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Compulsivity of alcohol use
Number of subjects: 96
Study: 31908426

Group type: EXPERIMENTAL
Intervention: Disposable pen
Number of subjects: 116
Study: 31908441

Group type: EXPERIMENTAL
Intervention: Bronchodilator Responsiveness (BDR)
Number of subjects: 2974
Study: 31908444

Group type: EXPERIMENTAL
Intervention: GOLD D patients
Number of subjects: 3253

Group type: EXPERIMENTAL
Intervention: Daily variability in chest tightness and wheezing
Number of subjects: 3253
Study: 31908462

Group type: EXPERIMENTAL
Intervention: Higher PANSS positive dimension ratings
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Higher PANSS negative dimension ratings
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: PANSS depression ratings
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: More severe cognitive/disorganized PANSS symptoms
Number of subjects: 1379
Study: 31908520

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine combined with 2 μg/kg dexmedetomidine (LD group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.2% ropivacaine (H group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.1% ropivacaine (L group)
Number of subjects: 90
Study: 31908779

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Non-dexmedetomidine (non-DEX)
Number of subjects: 201
Study: 31908788

Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Daytime SpO2
Number of subjects: 332
Study: 31908791

Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5
Study: 31908813

Group type: EXPERIMENTAL
Intervention: Sildenafil (combined dose group)
Number of subjects: 234
Study: 31909303

Group type: EXPERIMENTAL
Intervention: Tadalafil and subcutaneous BNP
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 21
Study: 31910037

Group type: EXPERIMENTAL
Intervention: Quick Sepsis-related Organ Failure Assessment Score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31910750

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention for Hoarding Disorder (CTI-HD)
Number of subjects: 14
Study: 31910859

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 12806
Study: 31910885

Group type: EXPERIMENTAL
Intervention: Diaries completed continuously or intermittently
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigator-led interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diaries (general)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case report forms (CRFs) completed by investigators
Number of subjects: 0
Study: 31910916

Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Supportive Therapy for Cognitively Impaired Older Adults (ST-CI)
Number of subjects: 35
Study: 31911180

Group type: EXPERIMENTAL
Intervention: Neratinib + Sodium Valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knock down of ERBB3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copanlisib
Number of subjects: 0
Study: 31911527

Group type: EXPERIMENTAL
Intervention: Perioperative covert stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive function evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum immune-inflammatory cytokines
Number of subjects: 0
Study: 31911839

Group type: EXPERIMENTAL
Intervention: Rituximab (MabThera)
Number of subjects: 0
Study: 31912137

Group type: EXPERIMENTAL
Intervention: CNC patients with systematic follow-up and screening for manifestations
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CNC patients with systematic follow-up
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CNC patients with PRKAR1A c.709-7del6 mutation
Number of subjects: 70
Study: 31912154

Group type: EXPERIMENTAL
Intervention: Cushing's syndrome patients in remission
Number of subjects: 36
Study: 31912203

Group type: EXPERIMENTAL
Intervention: 2004 study
Number of subjects: 26024

Group type: EXPERIMENTAL
Intervention: 2010 study
Number of subjects: 26024

Group type: EXPERIMENTAL
Intervention: 2016 study
Number of subjects: 26024

Group type: COMPARATOR
Intervention: 1998 study
Number of subjects: 26024
Study: 31912438

Group type: EXPERIMENTAL
Intervention: CCUS performed by medical students
Number of subjects: 1212

Group type: COMPARATOR
Intervention: CO measurements by experts
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: CCUS measurements by both medical students and experts
Number of subjects: 1212
Study: 31912454

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cannabidiol
Number of subjects: 0
Study: 31912462

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 31912493

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel (mean daily dose 7.0 mg/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel
Number of subjects: 180
Study: 31912874

Group type: EXPERIMENTAL
Intervention: Cold exposure
Number of subjects: 19
Study: 31912905

Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neratinib plus HDAC inhibitors
Number of subjects: 0
Study: 31912961

Group type: EXPERIMENTAL
Intervention: Kidney transplantation (Tx)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 31912991

Group type: EXPERIMENTAL
Intervention: cQFR
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: HFV
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: cQFR-fQFR
Number of subjects: 130